Novel CRTH2 antagonists: a review of patents from 2006 to 2009

Trond Ulven, Evi Kostenis

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

The receptor CRTH2 (also known as DP₂) is an important mediator of the inflammatory effects of prostaglandin D₂ and has attracted much attention as a therapeutic target for the treatment of conditions such as asthma, COPD, allergic rhinitis and atopic dermatitis.
Original languageEnglish
JournalExpert Opinion on Therapeutic Patents
Volume20
Issue number11
Pages (from-to)1505-30
Number of pages26
ISSN1354-3776
DOIs
Publication statusPublished - 1. Nov 2010

Fingerprint Dive into the research topics of 'Novel CRTH2 antagonists: a review of patents from 2006 to 2009'. Together they form a unique fingerprint.

Cite this